Pluristem Therapeutics Inc: (NASD: PSTI)

$2.79

-0.03 (-1.06%)

Volume 84,109

Jun 18 03:59 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		2.78 - 2.84
	
		52wk Low - High
		2.26 - 5.00
	
		Previous Close
		2.82
	
		Avg. Volume
		257,528
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		165.36 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		-0.03
	
		P/E (F1)
		0.00
	
		Current Year Est.
		-0.37
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		105 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 06/13/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.37
                        
                            Current Quarter Estimate
                            -0.09
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            09-09-2013
                        
                            EPS Last Year
                            -0.35
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells.   
Full PSTI Company Report

 Snapshot on PSTI

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
PSTI Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (06/2013)	Next Year (06/2014)
Average Estimate	-0.09	-0.11	-0.37	-0.50
Number of Estimates	3	1	3	2
Low Estimate	-0.09	-0.11	-0.42	-0.62
High Estimate	-0.08	-0.11	-0.33	NA
Year Ago EPS	-0.09	-0.08	-0.34	-0.37
EPS Growth	3.70%	-37.50%	-7.84%	-36.36%

More PSTI Estimates

Average Earnings Estimates for PSTI

EPS Growth for PSTI

Industry Analysis

Name	Symbol	Previous Close
PLURISTEM THERA	PSTI	2.82
AETERNA ZENTARS	AEZS	1.90
ANIKA THERAPEUT	ANIK	16.55
BIOGEN IDEC INC	BIIB	207.75
PROTALIX BIOTHR	PLX	5.04
AASTROM BIOSCI	ASTM	0.51
ADDEX THERA LTD	ADDXF	3.95
AFFYMAX INC	AFFY	1.09
ALEXION PHARMA	ALXN	91.32
ALNYLAM PHARMA	ALNY	29.69

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Setback for Pluristem Therapeutics

Jun 05, 2013

PSTI Plans to Start Phase I Study

Apr 19, 2013

UTHR to Move PAH Drug into Phase I

Apr 15, 2013

Pipeline Progress at Pluristem

Mar 25, 2013

Pluristem & UTHR Progress with PLX-PAD

Mar 04, 2013

Pluristem Moves to New Facility

Jan 31, 2013

Pluristem Progresses with New Facility

Jan 04, 2013

Orphan Status Update from Pluristem

Nov 27, 2012

More PSTI Zacks Commentary

Financials

EPS TTM	-0.35
Sales	1
Net Income	-18
Price/Earnings	NA
Price/Book	2.57
Price/Cash Flow	NA
Price/Sales	241.40

More PSTI Financials

News

Pluristem CEO, Zami Aberman Answers the Tough Questions - Marketwire

Jun 6, 2013

Pluristem Issues Responses from CEO Aberman in Q&A, Says No Effect on PLX-PAD Other Trials Outside US - Benzinga

Jun 6, 2013

Downgrade Alert for PLURISTEM THERAPEUTICS (PSTI) - Comtex Smartrend(R)

Jun 5, 2013

Market Maker Surveillance Report. LPHI, MEG, BTX, PSTI, FBN, VRML, Losing Stocks With Lowest Price Friction For Tuesday, June 4th 2013 - M2

Jun 5, 2013

UPDATE: Jefferies Lowers PT on Pluristem Therapeutics Following Phase 2 Trial Suspension - Benzinga

Jun 5, 2013

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Pluristem Therapeutics, Inc. - Pr Newswire

Jun 4, 2013

Morning Market Losers - Benzinga

Jun 4, 2013

Pluristem to Receive Clinical-hold Notice From the U.S. FDA - Globenewswire

Jun 4, 2013

See All News Stories on PSTI

Broker Recommendations

Current ABR	1.75
ABR (Last Week)	1.75
# of recs in ABR	4
Average Target Price	4.50
Industry Rank by ABR	105 out of 265
Rank in Industry	31 out of 153

More PSTI Broker Recommendations

Day Low - High	2.78 - 2.84
52wk Low - High	2.26 - 5.00
Previous Close	2.82
Avg. Volume	257,528
Industry	MED-BIOMED/GENE
Market Cap	165.36 M
Div - Yield	0.00 - 0.00
Beta	-0.03
P/E (F1)	0.00
Current Year Est.	-0.37
Quarterly Earnings ESP	NA

P/E (F1)	NA
PEG Ratio	NA
Current Year Est.	-0.37
Current Quarter Estimate	-0.09
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	09-09-2013
EPS Last Year	-0.35
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Pluristem Therapeutics Inc: (NASD: PSTI)

$2.79

-0.03 (-1.06%)

Volume 84,109

Jun 18 03:59 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations